Product image of Mapoli (Sitagliptin) supplied by GNH India

Mapoli

Active Ingredient:
Sitagliptin
Origin:
EU

Mapoli (Sitagliptin)

Sitagliptin, the active ingredient in Mapoli, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It helps lower blood glucose in adults with type 2 diabetes mellitus.

GNH India supplies Mapoli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Glenmark Pharmaceuticals S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mapoli (sitagliptin) is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance.
  • Type 2 diabetes mellitus: improves glycemic control as an adjunct to diet and exercise.
  • Type 2 diabetes mellitus (monotherapy): provides glucose lowering when metformin is not tolerated.
  • Type 2 diabetes mellitus (combination therapy): enhances overall HbA1c reduction when used with other oral antidiabetics.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which results in increased levels of the incretin hormones GLP‑1 and GIP. Elevated incretins enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, thereby lowering post‑prandial and fasting blood glucose concentrations.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient mild to moderate pain.
  • Upper respiratory tract infection: symptoms of cough and congestion.
  • Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort.
  • Dizziness: occasional light‑headed sensation.
  • Joint pain: arthralgia without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Bullous pemphigoid: blistering skin disorder.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Acute kidney injury: reduced renal function in susceptible patients.
  • Hypersensitivity pneumonitis: rare lung inflammation.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal function: assess creatinine clearance and adjust dose if necessary.
  • History of pancreatitis: monitor for recurrent abdominal pain.
  • Hypersensitivity: discontinue if rash, pruritus, or angioedema develop.
  • Cardiovascular risk: use with caution in patients with heart failure.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Sitagliptin may interact with other medicines. Review the following:

Major Interactions (Avoid)

  • Insulin: combined use can increase risk of hypoglycemia.
  • Sulfonylureas (e.g., glipizide): may potentiate hypoglycemic episodes.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce sitagliptin exposure, lowering efficacy.
  • Diuretics: can affect glucose control, requiring monitoring.
  • ACE inhibitors: may enhance antihypertensive effect, watch blood pressure.

Frequently Asked Questions

Mapoli contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It is used to improve blood glucose control in adults when diet, exercise, and other oral agents are insufficient.

Sitagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances insulin secretion and reduces glucagon release in a glucose‑dependent manner, leading to lower blood sugar levels.

The prescribed dose of Mapoli is determined by the treating physician based on the patient’s renal function, glycemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Mapoli, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycemia because its glucose‑dependent mechanism requires elevated blood sugar to act. Unlike metformin, it does not affect gastrointestinal motility, making it an alternative for patients who cannot tolerate metformin.

Mapoli should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Mapoli is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events linked to sitagliptin include acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin conditions like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or swelling.

Mapoli is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is advised for individuals with severe renal impairment, a history of pancreatitis, or those who are pregnant or breastfeeding unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT